2014 PBCC

Metastatic Breast Ca

- Kathryn Peroutka, MD
- Andrews/Patel Associates
- Email kperoutka@andrewspatel.com

Let's talk about you

- Average woman in this country
- Risk of getting breast cancer
- How about the risk of that cancer recurring?
- That risk is tied to initial stage and associated risk factors

numbers

- About ½ of women presenting with breast cancer will have stage 1 disease
- About 1/2 of women will have stage 2
- About 70% will have ER/PR pos cancers.
- About 20% will have HER 2 pos cancers.

numbers

- Stage 1 ER positive breast cancer 57yo
- no additional therapy: DFS 71
- with adjuvant therapy: DFS 90
- Stage 2 ER positive 57 yo
- no additional therapy, DFS 60
- with adjuvant therapy, DFS 76
- 10 year numbers; DFS=disease free survival

numbers

- Stage 1 ER neg
- no therapy 70
- aduvant therapy 84
- Stage 2 ER neg
- no therapy 55
- adjuvant therapy 75

When does a recurrence happen?

Average: ER positive: longer ER negative: shorter

Your cancer is back.

What does it mean?

- What does it mean to say that you have metastatic breast cancer?
- How long will you live?
- How well will you live?
- What kind of therapy?
- What is the chance of cure?

Metastatic Breast Cancer

- Local
- Distant bones
- lung
- liver
- brain
- other
- combination

What does metastatic disease look like?













What about therapy?

Therapy

- Local Therapy: Surgery
 Radiation
- Systemic Therapy
 Chemotherapy
 Antiestrogen therapy
 Bone Strengtheners
 Targeted Therapy



What's new

- Antiestrogen Therapy?
- HER 2 positive therapy?
- Therapy for triple negative breast cancer?
- What else?

ER positive CA

- Antiestrogens Tamoxifen and other SERMS
- Aromatase Inhibitors anastrozole, letrozole, exemestane
- Fulvestrant



Newer

- Adding everolimus to aromatase inhibitors
- Bolero Study
 725 women on AI, progressed
 1 exemestane
 2 exemestane and everolimus

BENEFIT 5 months of PRF

HER 2 pos CA?

Traztuzumab

Lapatinib

Traztuzumab/emtansine - Kadcyla conjugate

Pertuzumab





HER 2 therapy

- Blocks HER 2
- Approved 2012 but not for all patients
- New Results last month for metastatic breast cancer
- 808 women
- chemo/traztuzumab/pertuzumab

chemo/traztuzumab/placebo

with 56 months without 41

Triple Neg breast CA?

- Triple negative ER neg/PR neg/HER 2 neg
- So we can't use antiestrogens or anti HER 2 agents
- Chemotherapy

Triple Neg

- Recent trial
- 450 woman stage 2 or stage 3
- 1 Cytoxn/Adria/Taxol
- 2 ACT plus carboplatin
- 3 ACT plus Avastin
- Neoadjuvant therapy What?

Whatever?

- Whatever happened to PARP inhibitors?
- PARP is "a correction enzyme"
- Showing promise in patients with BRCA
- Jury still out for TNC



What else?

• PD and PDL therapy



Let's Cure this disease... so our daughters won't have to



You are not alone.

Thank you